-
O287664-100mgApplication:3,5-Dinitrocatechol (3,5-DNC) has been used in the preparation of the molybdenum (VI)-(3,5-DNC) complex. It has also been used as a catechol-O-methyltransferase (COMT) inhibitor and as a positive control for screening human COMT
-
O287664-10mgApplication:3,5-Dinitrocatechol (3,5-DNC) has been used in the preparation of the molybdenum (VI)-(3,5-DNC) complex. It has also been used as a catechol-O-methyltransferase (COMT) inhibitor and as a positive control for screening human COMT
-
O287664-50mgApplication:3,5-Dinitrocatechol (3,5-DNC) has been used in the preparation of the molybdenum (VI)-(3,5-DNC) complex. It has also been used as a catechol-O-methyltransferase (COMT) inhibitor and as a positive control for screening human COMT
-
O286758-10mgSelective p38α/β inhibitor.
-
O286758-50mgSelective p38α/β inhibitor.
-
Ab177919-100μgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab177919-10mgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab177919-1mgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
Ab177919-5mgOS2966 (anti-ITGB1) is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity.
-
O288317-100mgSelective PARP-10 inhibitor.
-
O288317-10mgSelective PARP-10 inhibitor.
-
O288317-200mgSelective PARP-10 inhibitor.